(Bloomberg) — A brutal year for US stocks is drawing to a close with little conviction on Wall Street that the outlook is brightening anytime soon. After charting a rebound since October on speculation the Federal Reserve is nearing the end of its most aggressive rate hikes in decades, stock prices have retreated over the […]
Read MoreAkero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. […]
Read More(Bloomberg) –Private equity will have to get the check book out in the coming months if the industry wants to return to its record pace of deal making. That’s because banks stuck with billions of dollars of risky corporate loans, a hangover from deals underwritten in a lower-rate environment, are unlikely to back sizable new […]
Read More(Bloomberg) — European bondholders are coming to terms with the fact that this year’s devastating losses may have further to run in 2023. The worst-ever year for the region’s bonds is ending with one of the most brutal sell-offs in months, after a chorus of central bankers warned investors that interest rates will rise more […]
Read More